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The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene is considered the EBV oncogene
as it is necessary for EBV-mediated transformation of B lymphocytes and itself transforms rodent
fibroblasts. LMP1 activates the NF-B, phosphatidylinositol 3-kinase (PI3K)-Akt, mitogen-activated
protein kinase, and Jun N-terminal protein kinase signaling pathways through its two signaling domains,
carboxyl-terminal activating regions 1 and 2 (CTAR1 and CTAR2). CTAR1 and CTAR2 induce signal
transduction pathways through their direct (CTAR1) or indirect (CTAR2) recruitment of tumor necrosis
factor receptor-associated factors (TRAFs). CTAR1 is necessary for LMP1-mediated transformation as
well as activation of PI3K signaling and induction of cell cycle markers associated with G1/S transition.
In this study, activation of PI3K-Akt signaling and deregulation of cell cycle markers were mapped to the
TRAF-binding domain within CTAR1 and to the residues between CTAR1 and CTAR2. LMP1 CTAR1 also
activated the MEK1/2–extracellular signal-regulated kinase 1/2 signaling pathway, and this activation was
necessary for LMP1-induced transformation of Rat-1 fibroblasts. Dominant-negative forms of TRAF2 and
TRAF3 inhibited but did not fully block LMP1-mediated transformation. These findings identify a new
signaling pathway that is uniquely activated by the TRAF-binding domain of LMP1 and is required for
transformation.
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that is
associated with a variety of malignancies, including nasopha-
ryngeal carcinoma, Hodgkin’s lymphoma, posttransplant lym-
phoma, and others (29, 42, 55, 56). The EBV-encoded latent
membrane protein 1 (LMP1) gene is considered the EBV
oncogene as it is essential for EBV-mediated B-lymphocyte
transformation and itself can transform rodent fibroblasts (2,
28, 51). LMP1 is frequently expressed in EBV malignancies,
including nasopharyngeal carcinoma and Hodgkin’s lymphoma
(19, 55).
LMP1 consists of 386 amino acids that form a short 23
amino-terminal cytoplasmic end, six hydrophobic transmem-
brane domains, and a long carboxyl-terminal tail that contains
the two main signaling domains, carboxyl-terminal activating
regions 1 and 2 (CTAR1 and CTAR2). LMP1 self-associates in
the plasma membrane. Not requiring a ligand, LMP1 acts as a
constitutively active tumor necrosis factor receptor (TNFR) by
mediating signaling through the recruitment of TNFR-associ-
ated factors (TRAFs) by CTAR1 or through recruitment of
adapter molecules, such as the TNFR-associated death domain
or the receptor-interacting protein 1 by CTAR2 (24, 26, 38).
CTAR1 recruits TRAF1/2 or TRAF3/5 heterodimers through
a consensus TRAF-binding domain (PQQAT), whereas
CTAR2 recruits TRAF2 and TRAF6 through adapter mole-
cules (29).
LMP1 activates multiple signaling pathways, including NF-
B, mitogen-activated protein kinase, c-Jun N-terminal kinase,
and phosphatidylinositol 3-kinase (PI3K)-Akt pathways (10,
17, 26, 33, 37, 41, 43, 49). LMP1 also induces the deregulation
of various cellular markers associated with G1/S cell cycle tran-
sition, including the upregulation of the inhibitor of differen-
tiation 1 (Id1) and Id3, downregulation of cyclin-dependent
kinase inhibitors p27Kip1 and p16INK4a, upregulation of cyclin-
dependent kinase 2 (CDK2), and upregulation of retinoblas-
toma (Rb) (18, 30, 40).
Although both CTAR1 and CTAR2 recruit TRAFs, they
yield different effects on the signal transduction pathways they
activate. CTAR1, but not CTAR2, is necessary for rodent
fibroblast transformation and EBV-mediated B-lymphocyte
transformation (26, 33). Although CTAR2 more strongly acti-
vates NF-B in reporter assays, CTAR1 induces a more com-
plex signal, inducing both canonical and noncanonical forms of
NF-B, including p50/p50 and p50/p52 dimers (15, 27, 35, 50).
While CTAR2 activates the Jun N-terminal protein kinase
(JNK) signaling cascade, CTAR1 activates PI3K-Akt signaling,
resulting in the phosphorylation of the Akt target, glycogen
synthase kinase 3 (GSK3). CTAR1 also has unique effects
on cellular gene expression, including the induction of epithe-
lial growth factor receptor (EGFR), TRAF1, Id1, and Id3
while repressing p27Kip1 (11, 12, 14, 18, 33, 36). The activation
of PI3K-Akt, but not NF-B, is required for Rat-1 fibroblast
transformation (33).
The presence or absence of a specific TRAF can determine
the outcome of the signal being transduced by LMP1. Al-
though CTAR2, but not CTAR1, activates JNK signaling in
epithelial cells, overexpression of TRAF1 allows CTAR1 to
activate JNK signaling (16). In TRAF2 and TRAF5 knockout
mouse embryo fibroblasts (MEFs), LMP1-mediated NF-B
activation is similar to wild-type MEFs, and this activation is
highly dependent on TRAF6 (32). In contrast, in mouse lym-
phoma cells, NF-B and immunoglobulin M secretion are al-
most completely TRAF3 dependent (53, 54).
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In this study, the roles of the TRAF-binding domain,
TRAF2, and TRAF3 in rodent fibroblast transformation and
signal transduction were evaluated. LMP1 mutants with muta-
tions in the carboxyl-terminal tail and the TRAF-binding do-
main revealed that CTAR1 mediates the majority of PI3K-Akt
signaling and deregulation of cellular markers associated with
G1/S transition and induces a decrease in the protein levels of
the desmosome-associated protein plakoglobin. The activation
of extracellular signal-regulated kinases 1 and 2 (ERK1/2) was
uniquely activated by CTAR1, and this activation was neces-
sary for LMP1-mediated transformation of rodent fibroblasts.
Inhibition of TRAF2 or TRAF3 signaling using dominant-
negative TRAFs (dnTRAFs) impaired LMP1-induced trans-
formation of Rat-1 cells and decreased activation of ERK1/2.
These data identify a signaling pathway that is uniquely acti-
vated by CTAR1 and is necessary for LMP1-mediated trans-
formation.
MATERIALS AND METHODS
Plasmids. LMP1 and LMP1 mutants were cloned into the pBabe-puromycin
vector with a hemagglutinin (HA) tag at the amino terminus. LMP1-A5 (204-
208AAAAA), LMP1204-208, LMP1-204/6AA, and LMP1-208A were sub-
cloned from plasmids described in reference 35 into pBabe-puromycin with the
same primers used to clone full-length LMP1 in reference 18. Truncation mu-
tants with unaltered CTAR1 were constructed using the full-length LMP1 con-
struct, and truncation mutants with a mutated CTAR1 (A5) were constructed
using the LMP1-A5 construct. PCR amplification of the LMP1 mutants used the
same 5 primer (LMP1-HA5 used to clone full-length LMP1), but different 3
primers were used to produce the various constructs. The 1-187 construct was
produced with 3 primer 3TMSTOP (ATCACGAGGAATTCCTATTAATGGT
AATACATCCAGATTAAAATCGCC), 1-195 with the 3 primer 3TM195 (ATC
ACGAGGAATTCCTATTAGTGTTCATCACTGTGTCGTTGTC), 1-203 with
the 3 primer 3TM203 (ATCACGAGGAATTCCTATTAGTGCGGGAGGGAG
TCATC), 1-208 with the 3 primer TM-208 (ATCACGAGGAATTCCTATTAGG
TAGCTTGTTGAGGGTGCG), 1-208-A5 with the 3 primer TM-2085A (ATCA
CGAGGAATTCCTATTAGGCAGCTGCTGCAGCGTG), 1-220 and 1-220 A5
with the 3 primer 3TM220 (ATCACGAGGAATTCCTATTAGTTGGAGTTAG
AGTCAGATTCATGG), LMP1-378Stop and A5-378Stop with the 3 primer
378STOP (ATCACGAGGAATTCCTATTAGCCGTGGGGGTCGTCATC), and
LMP1-Y384G and A5-Y384G with the 3 primer Y384G (ATCACGAGGAATTC
CTATTATTAGTCATAGCCGCTTAGCTGAACTGG). PCR amplification was
monitored by restriction enzyme digestion and insertion into the BamHI and EcoRI
sites of pBabe-puromycin-M3 (with a puromycin or hygromycin cassette and con-
taining a triple myc tag [M3]).
An expression cassette encoding three tandem myc epitope tags was moved
from M3-LMP1 (18) to pBabe-puromycin for retroviral expression of myc-tagged
proteins. The myc tag was amplified with M3EBH5 (CGCCGGATCCAGATC
TAAGCTTGCCGCTCGAGCCACCATGGAACAAAAG) and M3Bam3 (CG
TGTTCCATATGGATCCGAG), digested with BglII and BamHI, and cloned
into the BamHI site of pBabe-puromycin. Cloning in frame with the myc tag
results in triple-myc-tagged proteins.
The dnTRAF6 construct was a gift from Ilona Jaspers (8). dnTRAF2 and
dnTRAF3 were subcloned in frame into pBabe-puromycin-M3 (containing a
triple myc tag) from plasmids described in reference 37. dnTRAF2 was PCR
amplified with the 5 primer TRF2DN5 (CGACGGATCCATAGGGAGGTG
GAGAGCCTGCCG) and the 3 primer TRF2DN3 (ATCACGAGGTCGAC
TTAGAGCCCTGTCAGGTCCACAATGG). dnTRAF3 was PCR amplified
with the 5 primer TRF3DN5 (CGACGGATCCTAGAGGAAGCAGACAGC
ATGAAGAGCAG) and the 3 primer TRF3DN3 (ATCACGAGGTCGACT
CAGGGATCGGGCAGATCCGAAG). PCR amplification was followed by re-
striction enzyme digestion and insertion into the BamHI and SalI sites of pBabe-
puromycin-M3 (puromycin and hygromycin). The 1-231 construct was described
previously (18).
LMP1 was cloned into retroviral packaging vector pHSCG (kindly provided by
Lishan Su, University of North Carolina at Chapel Hill [9]) coexpressing green
fluorescent protein under the control of the cytomegalovirus promoter. HA-
tagged LMP1 was amplified using HA-EcoRI (GCCGAATTCATGGCTTACC
CATACGATGTTCCAG) and LMP1 SalI (GCGGTCCAGAATGTGGCTTTT
CAGCCTAGAC) primers, digested with EcoRI and SalI, and ligated into the
EcoRI and XhoI sites of pHSCG by compatible ends.
Retrovirus production and transduction. Retroviruses were produced as de-
scribed previously (18). Briefly, subconfluent HEK-293T cells were triple trans-
fected with 5 g of pBabe-puromycin or pHSCG or each of the pBabe-puromy-
cin-HA-tagged LMP1 constructs or pHSCG-LMP1, 5 g of pVSVG, and 5 g of
pGag/Pol using Fugene 6 (Roche) transfection reagent according to the manu-
facturer’s directions. Following overnight incubation at 37°C, the medium was
replaced with fresh medium (Dulbecco modified Eagle medium [DMEM]
[GIBCO] with 10% fetal bovine serum [FBS] [Sigma] and antibiotic/antimycotic
[GIBCO]), and the cells were incubated at 33°C overnight. Cell supernatant
containing the retrovirus was clarified by centrifugation at 1,000  g for 5 min.
Rat-1 cells were then transduced with the clarified supernatant and 4 g/ml
Polybrene overnight.
Cell culture and stable cell lines. Rat-1 fibroblasts and HEK-293T cells were
maintained in DMEM supplemented with 10% FBS (Sigma) and antibiotic/
antimycotic (GIBCO). Rat-1 cells were prepared fresh and maintained for no
more than five passages for each experiment. Stable cell lines with pBabe-
puromycin, the LMP1 constructs, or the dnTRAFs were established by trans-
duction with recombinant retrovirus followed by selection with 5 g/ml of pu-
romycin (Sigma). Alternatively, cells stably expressing dnTRAF were kept under
hygromycin (Cellgro) at a concentration of 200 g/ml.
Focus formation and soft agars. Subconfluent Rat-1 cells were transduced
with recombinant retrovirus in six-well plates overnight. Cells were then main-
tained by changing the medium every other day for 10 to 14 days. To assay for
focus formation in the presence of U0126 (Calbiochem), stable cell lines were
established as described previously and seeded in duplicate six-well plates. Upon
reaching confluence and every other day thereafter for 7 to 10 days, fresh
medium containing 10 M U0126 or vehicle control (dimethyl sulfoxide from
Sigma) was added to the cells. Cells were then stained with 1% crystal violet in
50% ethanol and imaged with a stereomicroscope.
Soft agar assays were performed as described previously (33, 46). Briefly,
Bacto agar medium (5% Bacto agar in DMEM with 10% FBS and antibiotic/
antimycotic to a final concentration of 0.5%) was poured into a 12-well plate and
allowed to solidify. A total of 1.0  105 to 2.0  105 cells/well were resuspended
in Bacto agar medium, overlaid on the initial layer of solidified Bacto agar
medium, and allowed to solidify. Medium was added on top of the solidified
Bacto agar medium and changed every 2 or 3 days for 14 to 21 days. For the
dnTRAF soft agars, medium was supplemented with 5 g/ml of puromycin to
maintain stable expression of the dnTRAFs. Cells were imaged with phase-
contrast microscopy and fluorescence microscopy to verify green fluorescent
protein expression.
Cell harvesting and Western blotting. Cell lines were grown to confluence and
harvested as described previously (18). Briefly, after the cells were harvested,
they were washed with ice-cold phosphate-buffered saline (GIBCO), centrifuged
at 1,000  g, and lysed with radioimmunoprecipitation assay buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% sodium dodecyl
sulfate [SDS], 0.1% deoxycholate, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM
Na3VO4, and protease and phosphatase inhibitor cocktails from Sigma). Lysates
were incubated on ice for 10 min and clarified by centrifugation, and protein
concentration was determined using the Bio-Rad DC protein assay system.
Lysates were boiled in SDS sample buffer for 5 min, 12.5 or 25.0 g of protein
was separated by SDS-polyacrylamide gel electrophoresis and transferred to an
Optitran membrane (Whatman) for Western blot analysis, and efficient transfer
was confirmed with Ponceau S staining (Fluka). Primary antibodies used in-
cluded HA probe (Covance), CS1-4 (Dako), c-myc tag, -actin, TRAF6, phos-
pho-ERK1/2 (Y473), total ERK1/2, poly(ADP-ribose) polymerase (PARP)
(Santa Cruz), plakoglobin (Abcam), CDK2, Rb (BD Biosciences), total GSK3
(Upstate Biotechnology), phospho-Rb (Oncogene), p27Kip1 (Calbiochem and
Cell Signaling), phospho-GSK3 (S9), phospho-CDK2 (T160), phospho-Akt
(S473), phosphorylated protein kinase c zeta isoform (PKC-) (T410/403), and
total Akt (Cell Signaling). Densitometry analysis was done with Image J
software.
RESULTS
CTAR1 is necessary for rodent fibroblast transformation.
The LMP1 gene is considered the EBV oncogene as it is able
to block contact inhibition and induce anchorage-independent
growth in Rat-1 fibroblasts (18, 33, 51). Deletion mutants of
LMP1 indicated that CTAR1 but not CTAR2 was required for
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rodent fibroblast transformation (33). To assess the role of the
TRAF-binding site in rodent fibroblast transformation, two
TRAF-binding domain mutants were developed. LMP1-A5
has the TRAF-binding domain mutated from PQQAT to
AAAAA, and LMP1204-208 has a deletion of the TRAF-
binding domain encompassing amino acids 204 to 208. To
determine whether these constructs were able to block contact
inhibition, Rat-1 fibroblasts were transduced with pBabe-pu-
romycin (vector), LMP1, 1-231 (LMP1 deleted for amino acids
232 to 386), LMP1-A5, and LMP1204-208. Ten days post-
transduction, cells were analyzed for block of contact inhibi-
tion as indicated by focus formation (Fig. 1). As previously
described, LMP1 and 1-231, both of which contain CTAR1,
induced focus formation; however, foci were not produced by
pBabe-puromycin and the two TRAF-binding domain mu-
tants, LMP1-A5 and LMP1204-208. Western blot analysis on
cells transduced in parallel confirmed expression of all four
constructs, indicating that the failure to block contact inhibi-
tion was not due to failed transduction or expression (data not
shown). These data reveal that the TRAF-binding domain,
amino acids 204 to 208, is necessary for rodent fibroblast trans-
formation.
Role of CTAR1 in LMP1 signal transduction. To further
evaluate the role of CTAR1 in the induction of several signal
transduction pathways, additional LMP1 mutants were con-
structed (Fig. 2). Two full-length LMP1 mutants of CTAR1,
LMP1-204/6AA (two alanine substitutions at amino acids 204
and 206) and LMP1-208A (alanine substitution at amino acid
208), were subcloned to evaluate the role of the TRAF-binding
site within CTAR1. The serial truncation LMP1 mutants
ranged from the start of the carboxyl-terminal tail at amino
acid 188 to amino acid 231. Finally, a CTAR2 deletion mutant
(LMP1-378Stop) and a point mutant that has been described
to abrogate most CTAR2 activity (LMP1-Y384G) were con-
structed with a functional CTAR1 and a mutant CTAR1 (A5-
378Stop and A5-Y384G) (4, 20). All LMP1 constructs were
tagged hemagglutinin at the amino terminus.
Rat-1 fibroblasts stably expressing pBabe-puromycin, LMP1,
LMP1204-208, 1-187, 1-195, 1-203, 1-220, and 1-231 were
assayed for their ability to modulate three aspects of transfor-
mation that have been linked to LMP1: PI3K-Akt signaling,
cell cycle deregulation, and cellular adhesion (Fig. 3A). The
levels of expression of these targets were normalized to actin
and are presented as changes in induction from that of vector
control (Fig. 3B). Expression of LMP1 was confirmed using
antibodies against the amino-terminal HA tag. The variation in
the levels of LMP1 expression has been shown to result from
ubiquitination and proteasomal degradation mediated by
CTAR1-TRAF binding (44). As reported previously, full-
length LMP1 induced activation of the PI3K-Akt signaling
pathway as represented by phosphorylation and inactivation of
the Akt target, GSK3. The LMP1 mutants 1-220 and 1-231,
which are deleted for CTAR2, also slightly increased levels of
phosphorylated GSK3, although 1-231 had the strongest in-
duction. The deletion mutants (1-187, 1-195, and 1-203) were
impaired in their effects on GSK3. Interestingly, deletion of
the TRAF-binding domain in full-length LMP1 (LMP1204-
208) retained approximately 60% of the activity of full-length
LMP1 (Fig. 3B).
Increased levels of hyperphosphorylated CDK2 and in-
creased levels of total Rb, cellular markers involved in G1/S
cell cycle progression, were observed in LMP1, LMP1204-
208, 1-220, and 1-231. Total Rb levels have been demonstrated
to be increased concomitant with the hyperphosphorylated
form of Rb in the presence of LMP1, although the effect of the
increase in Rb levels remains to be determined (34). Plakoglo-
bin, a cellular protein associated with cell-cell adhesion, was
also downregulated by LMP1, LMP1204-208, 1-220, and
1-231. The ability of the nontransforming LMP1204-208 to
modulate GSK3, plakoglobin, CDK2, and Rb to levels similar
to those by the transforming 1-220 is surprising. Comparison of
the truncation mutants (1-187, 1-195, and 1-203) to those that
contain CTAR1 (1-220, and 1-231) indicated that the TRAF-
binding domain is required to affect these cellular pathways.
However, comparison of full-length LMP1 and LMP1204-
208 revealed that in addition to the TRAF-binding domain,
another region in the carboxy terminus can also contribute to
these effects on cell expression and regulation.
Mutations in CTAR1 ameliorate LMP1 transforming poten-
tial. Two residues within the TRAF-binding domain, the pro-
line at amino acid 204 and the glutamine at position 206, that
constitute CTAR1 have been found to have an important role
in TRAF binding (35). To further evaluate the roles of the
residues within CTAR1 in rodent fibroblast transformation,
Rat-1 cells were transduced with pBabe-puromycin, LMP1,
LMP1-A5, 1-195, 1-203, 1-208, 1-208-A5, 1-220, 1-220-A5,
1-231, LMP1-204/6AA, and LMP1-208A and assayed for the
ability to block contact inhibition and induce foci (Fig. 4). Cells
transduced with LMP1, 1-220, 1-231, LMP1-208A, and LMP1-
204/6AA formed foci, while cells transduced with truncation
mutants 1-195, 1-203, and 1-208 did not form foci. Cells trans-
duced with LMP1-204/6AA were impaired in this ability as
indicated by smaller foci. Cells transduced with LMP1-208A
formed foci to levels similar to those of cells transduced with
LMP1, indicating that the threonine residue at position 208 in
the TRAF-binding site is not necessary for transformation.
Although cells transduced with 1-208 did not form foci even
though the TRAF-binding site is intact, previous studies have
shown that the aspartic acid residue at position 210 is necessary
FIG. 1. The TRAF-binding domain is necessary for LMP1-medi-
ated block of contact-inhibited growth. Rat-1 fibroblasts were trans-
duced with pBabe-puromycin (pBabe), LMP1, 1-231, LMP1-A5, or
LMP1204-208, maintained for 10 days, stained with crystal violet, and
observed for focus formation.
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for TRAF3 binding, suggesting that 1-208 could be non-
transforming due to this TRAF-binding defect (52). Fur-
thermore, substitution of CTAR1 to all alanine residues
(LMP1-A5 or 1-220-A5) or deletion of CTAR1 (1-195 or
1-203) inhibited transformation. These data indicate that
the TRAF-binding site is required for transformation and
that additional residues between amino acids 208 and 220
contribute to its function.
Effects of mutation of the TRAF-binding domain on LMP1
signaling. To evaluate the roles of CTAR1 and the amino acids
surrounding CTAR1 in LMP1-mediated signal transduction,
Rat-1 cells stably expressing LMP1 and several LMP1 mutants
were established and their ability to induce various signal
transduction pathways was assessed through Western blot
analysis (Fig. 5). LMP1, 1-208, 1-220, 1-231, and LMP1-208A
had increased phospho-GSK3. Mutation (LMP1-A5) or de-
letion (LMP1204-208) of the TRAF-binding site within full-
length LMP1 slightly decreased this induction (Fig. 5). In con-
trast, mutation of the TRAF-binding site within truncated
LMP1 (1-208-A5 or 1-220-A5) abolished the effect of LMP1 on
the level of phospho-GSK3 (Fig. 5). Similarly, total Rb levels
were upregulated by LMP1, LMP1-A5, 1-220, 1-231, and
LMP1-208A (Fig. 5). Although full-length LMP1204-208,
LMP1-A5, and 1-208 are nontransforming, they all affected
the levels of phosphorylated GSK3 and total Rb. Within the
truncated forms of LMP1, 1-208, or 1-220, mutation of the
TRAF-binding site inhibited the ability of LMP1 to modulate
GSK3 and Rb. Similar effects were observed with total levels
of CDK2 (Fig. 5). With some of the mutants that had reduced
but detectable activity, these markers were not uniformly af-
fected in all experiments. For example, in the experiment pre-
sented, 1-208 clearly affected pGSK3 and CDK2 but had
minimal effects on Rb. The overall assessment of the effects of
LMP1 and the various mutants on these cellular proteins is
presented in Table 1. These data confirm that sequences be-
tween CTAR1 and CTAR2 can compensate for the loss of the
FIG. 2. Graphical representations of LMP1 mutants. All constructs are tagged at the amino terminus with HA. CTAR1 and CTAR2 are
represented by squares with the number 1 or 2 in the square, respectively. Substitutions to CTAR1 or CTAR2 are highlighted with an asterisk
above the mutated residue. The mutants in the bottom two rows are truncation mutants.
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FIG. 3. CTAR1 induces activation of PI3K-Akt signaling and deregulates markers associated with cell cycle progression. (A) Rat-1 cells
stably expressing pBabe-puromycin (pBabe), LMP1, or LMP1 mutants were assayed by Western blot analysis for expression of LMP1
constructs with antibodies against HA, phosphorylated GSK3 (p-GSK3) (S9), total GSK3 (	 and  forms), plakoglobin, CDK2 (hyper-
phosphorylated CDK2 is marked by the arrowhead), total Rb, and actin as a loading control. (B) Quantitative analysis of protein levels of
pGSK3b (white bars), plakoglobin (black bars), and Rb (stippled bars). Values are changes in induction compared to the level induced by
pBabe-puromycin (pBabe).
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TRAF-binding domain and modulate the levels of pGSK3,
Rb, and CDK2.
Rat-1 cells stably expressing LMP1 and several LMP1 mu-
tants were also assayed for their ability to deregulate the cell
cycle marker p27Kip1 as well as the cell adhesion protein
plakoglobin (Fig. 6A). LMP1, LMP1-A5, 1-208, 1-220, 1-231,
LMP1-204/6AA, and LMP1-208A decreased the protein levels
of p27Kip1 and plakoglobin. Similar to the effects on pGSK3,
Rb, and CDK2, mutation of the TRAF-binding site in full-
length LMP1 (LMP1-A5) did not affect the LMP1-induced
downregulation of p27Kip1 and plakoglobin. However, the
TRAF-binding site in 1-208 or 1-220 was absolutely required
for the LMP1-mediated decrease of p27Kip1 and plakoglobin
(Fig. 6). In addition, the mutations within the TRAF domain in
LMP1-204/6AA and LMP1-208A did not affect the ability of
LMP1 to decrease p27Kip1 and plakoglobin. These findings
reveal that the effect of LMP1 on these cellular markers does
not correlate with the ability to transform Rat-1 cells, as
LMP1-A5 and 1-208 are nontransforming but still modulate
these cellular markers. The data suggest that the TRAF-bind-
ing site is the main effector in the induction of PI3K-Akt
signaling, as measured by GSK3 phosphorylation, the dereg-
ulation of cell cycle markers Rb and p27Kip1, and the cell
adhesion marker plakoglobin. However, the data also confirm
that in the absence of the TRAF-binding site, sequences be-
tween CTAR1 and CTAR2 can also modulate these cellular
markers. Interestingly, all of the truncated forms of LMP1
(1-195, 1-203, 1-208-A5, and 1-220-A5) that lack the TRAF
domain and the sequences between CTAR1 and CTAR2
actually increased the levels of p27Kip1 and plakoglobin com-
pared to the vector control.
ERK1/2 activation is necessary for LMP1-mediated trans-
formation. LMP1 has been shown to induce activation of mi-
togen-activated protein kinase and ERK1/2 in Rat-1 fibroblasts
FIG. 4. Transformation by LMP1 CTAR1 mutants. Rat-1 cells were transduced with pBabe-puromycin (pBabe), LMP1, or LMP1 mutants,
maintained for 14 days, stained with crystal violet, and observed for focus formation.
FIG. 5. Effects on LMP1-induced inactivation of GSK3 and cell
cycle markers by LMP1 CTAR mutants. Rat-1 cells stably expressing
pBabe-puromycin (pBabe), LMP1, or LMP1 mutants were assayed for
LMP1 expression with antibodies against HA, phosphorylated GSK
(p-GSK), total GSK3 (	 and  subunits), actin as a loading control,
total Rb, and total CDK2.
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and in T cells (7, 43). To determine the role of CTAR1 in
ERK1/2 activation, Rat-1 cells stably expressing pBabe-puro-
mycin, LMP1, or various LMP1 constructs were assayed for
ERK1/2 activation by Western blot analysis (Fig. 7A). Densi-
tometry analysis was performed to quantitate the levels of
phosphorylated ERK1/2 (Fig. 7B). All of the LMP1 mutants
that contained the TRAF-binding domain (LMP1-204/6AA,
LMP1-208A, LMP1-Y384G, LMP1-378Stop, and 1-220) had
significantly increased levels of phosphorylated ERK1/2. Mu-
tation or deletion of CTAR2 (LMP1-Y384G, A5-Y384G,
LMP1-378Stop, or A5-378Stop), whether in the presence or
absence of a wild-type TRAF-binding site, did not affect the
levels of phosphorylated ERK1/2 or p27Kip1. In contrast to
that observed with phosphorylated GSK3, Rb, p27Kip1, and
plakoglobin, activation of ERK1/2 was detected only in cells
expressing LMP1 constructs that were transforming. LMP1-A5
and 1-220-A5, which are nontransforming, had significantly
reduced levels of phospho-ERK1/2 compared to LMP1 and
1-220, which are transforming. These data indicate that
ERK1/2 activation is mediated strictly by the TRAF-binding
site and that the CTAR1-mediated activation of ERK1/2 is a
major factor in LMP1-mediated transformation of rodent fi-
broblasts.
To evaluate the requirement of MEK1/2 and ERK1/2 sig-
naling to LMP1-mediated transformation, parallel sets of sta-
ble Rat-1 cells were treated for 7 days with dimethyl sulfoxide
or 10 M U0126, a MEK1/2 chemical inhibitor. Cells were
then observed for focus formation or assessed for ERK1/2
activation by Western blot analysis. U0126 treatment abolished
the LMP1-mediated block of contact inhibition as measured by
focus formation. U0126 treatment equally inhibited focus for-
mation induced by the various LMP1 mutants (Table 1).
U0126 also blocked LMP1-induced ERK1/2 activation, and
LMP1 expression levels in the presence and absence of U0126
were confirmed by Western blot analysis to ensure that the
effects on contact inhibition were not due to lack of LMP1
expression (data not shown). These data indicate that ERK1/2
activation is necessary for LMP1-mediated transformation of
Rat-1 fibroblasts. The relationship of activation of these path-
ways to transformation is presented in Table 1.
LMP1-mediated transformation is impaired by dnTRAF2
and dnTRAF3. The interaction of CTAR1 with several
TRAFs, including TRAF1, -2, -3, and -5, mediates the activa-
tion of signal transduction pathways, such as NF-B and in-
duction of key progrowth cellular molecules like the EGFR (5,
12, 13, 35, 37, 53). To determine whether TRAF2 and/or
TRAF3 mediates the ability of LMP1 to block contact-inhib-
ited growth, Rat-1 cell lines stably expressing pBabe-puromy-
cin-M3, dnTRAF2, or dnTRAF3 were established and then
transduced with serial dilutions of either pBabe-puromycin or
LMP1. Cells on duplicate plates were harvested, and expres-
sion of the dnTRAFs and LMP1 was confirmed by Western
blot analysis indicating reduced levels of nuclear NF-B iso-
forms p50 and p65 (data not shown). dnTRAFs contain the
TRAF-binding domain but have been deleted of their RING
and zinc finger domains, thus allowing interaction with their
target molecule while impairing their ability to induce signaling
upon their recruitment. Fourteen days posttransduction, cells
were observed for focus formation (Fig. 8A). Transduction of
the pBabe-puromycin-M3 (vector) stable cells with pBabe-pu-
romycin (pBabe-puromycin-M3–pBabe-puromycin) or the sta-
ble cells expressing only dnTRAF2 or dnTRAF3 did not show
signs of focus formation. In contrast, transduction of the
pBabe-puromycin-M3, dnTRAF2, or dnTRAF3 stable cells
with LMP1 resulted in focus formation. Although dnTRAF2
or dnTRAF3 did not completely ablate focus formation, they
markedly reduced the number of foci.
Quantitative analysis from a representative experiment of
the foci indicate that dnTRAF2 and dnTRAF3 repressed focus
formation by approximately 2.5-fold (Fig. 8B). Furthermore,





p-GSK3 p27Kip1 Plakoglobin p-ERK1/2
LMP1 Yes Yes    


















LMP1-204/6AA Yesc Yes    
LMP1-208A Yes Yes    
LMP1-Y384G Yes Yes    









LMP1-378Stop Yes Yes    








1-187 No Yes   
 NC
1-195 No Yes   
 NC
1-203 No Yes   NC NC









1-208-A5 No Yes    NC
1-220 Yes Yes    
1-220-A5 No Yes    NC
1-231 Yes Yes    
a LMP1 and LMP1 mutants that are transforming are shown in boldface type.
b The level of protein (phosphorylated GSK3 p-GSK3 and phosphorylated ERK1/2 pERK1/2) compared to the level of the control is shown. Plus signs indicate
a level higher than that of the control, while minus signs indicate a level lower than that of the control. The number of symbols indicates levels of change from vector
control, with more symbols indicating a greater level of change. NC, no change compared to that of the control.
c Decreased transformation potential.
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anchorage-independent growth was also impaired, but not fully
blocked, by either dnTRAF2 or dnTRAF3 (data not shown).
To confirm the specificity of the inhibition on LMP1-mediated
transformation by dnTRAF2 and dnTRAF3, Rat-1 cells stably
expressing dnTRAF6 were transduced with LMP1 and assayed
for focus formation. TRAF6 is recruited to LMP1 and signals
specifically through CTAR2, not CTAR1 (47), and as such
LMP1-mediated focus formation was not impaired by the sta-
ble expression of dnTRAF6 (data not shown). These data
suggest that TRAF2 and TRAF3, but not TRAF6, contribute
to LMP1-mediated transformation of rodent fibroblasts. The
inability of dnTRAF2 and dnTRAF3 to fully block LMP1-
mediated transformation suggests a redundancy in TRAF
function. Indeed, in TRAF2 and TRAF5 knockout MEFs,
LMP1 can still mediate nuclear translocation of the NF-B
subunit p65 (31).
To determine the roles of TRAF2, TRAF3, and TRAF6 in
the modulation of LMP1-mediated activation of ERK1/2,
Rat-1 cells stably expressing pBabe-puromycin, dnTRAF2,
dnTRAF3, or dnTRAF6 were transduced with vector (pHSCG)
or LMP1, followed by Western blot analysis (Fig. 9). Expression
of LMP1 was confirmed with a pool of monoclonal antibodies to
FIG. 6. Effects on deregulation of p27Kip1 and plakoglobin levels by LMP1 CTAR mutants. (A) Rat-1 cells stably expressing pBabe-puromycin
(pBabe), LMP1, or LMP1 mutants were assayed for LMP1 expression with antibodies against HA, p27Kip1, plakoglobin, or actin as a loading
control by Western blot analysis. (B) Quantitative analysis of p27Kip1 (black bars) and plakoglobin (white bars) protein levels. Values shown are
changes in induction compared to the level induced by pBabe-puromycin (pBabe).
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LMP1, while expression of myc-tagged dnTRAF2 and dnTRAF3
and of dnTRAF6 was confirmed with anti-myc or anti-TRAF6.
Interestingly, expression of dnTRAF2 was considerably higher
than expression of dnTRAF3. Expression of phosphorylated
ERK1/2 was significantly inhibited by dnTRAF2 and dnTRAF3
and partially affected by dnTRAF6. This finding suggests that
the effects of dnTRAF2 and dnTRAF3 on Rat1 transforma-
tion are likely mediated in part by their effects on ERK acti-
vation.
ERK1/2 activation can be mediated through the PI3K-de-
pendent activation of PKC-, which then activates MEK1/2 (3,
39). To determine the role of PKC- in LMP1-induced activa-
tion of ERK1/2, Rat-1 cells stably expressing LMP1 and
dnTRAF2, dnTRAF3, or dnTRAF6 were analyzed by Western
blotting. LMP1 expression increased the levels of phosphory-
lated PKC- in the control Rat-1 cells containing the vector
(pBabe-puromycin). Rat-1 cells stably expressing high levels
of dnTRAF2 did not impair PKC- phosphorylation, while
dnTRAF3 completely inhibited PKC- phosphorylation despite
its lower levels of expression. Expression of dnTRAF6 expression
FIG. 7. CTAR1 is necessary for LMP1-induced activation of ERK1/2. (A) pBabe-puromycin (pBabe), LMP1, or LMP1 mutants stably
expressed in Rat-1 cells were assayed by Western blot analysis for LMP1 expression (longer exposure shown in inset) with antibodies against HA,
phosphorylated ERK1/2 (pERK1/2) (Y204), total ERK1/2, p27Kip1, or actin as a loading control. (B) Quantitative analysis of phosphorylated
ERK1/2 protein levels. Values shown are changes in induction compared to the level induced by pBabe-puromycin (pBabe).
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moderately impaired this activity; however, dnTRAF6 expres-
sion activated PKC- in the absence of LMP1. Although
dnTRAF2 almost entirely inhibited the LMP1-induced
ERK1/2 activation, it did not affect PKC- phosphorylation. In
contrast, dnTRAF3 inhibited the activation of ERK1/2 to a
lesser degree than dnTRAF2 but completely blocked activa-
tion of PKC-. Total levels of PKC- were not detected due to
poor reactivity of the PKC- antiserum; therefore, equal pro-
tein loading was confirmed by Ponceau S staining.
These data suggest that LMP1 activation of ERK1/2 is me-
diated through TRAF2 and TRAF3 while the phosphorylation
of PKC- requires TRAF3 but not TRAF2. Due to the differ-
ences in expression of both dnTRAF2 and dnTRAF3, it is
difficult to determine the exact contribution of TRAF2 and
TRAF3 to the activation of PKC- and/or ERK1/2. However,
the ability of LMP1 to induce ERK phosphorylation in the
absence of phosphorylated, and activated, PKC- suggests that
PKC- phosphorylation is not necessary for LMP1-mediated
ERK activation.
DISCUSSION
The data presented in this study evaluated the roles of the
TRAF-binding site in LMP1-mediated transformation and
LMP1-mediated signal transduction. Several studies have char-
acterized the ability of LMP1 to recruit TRAFs (TRAF1, -2, -3,
and -5) to CTAR1 through a consensus TRAF-binding site at
positions 204 to 208 (5, 25, 35, 37, 38, 52, 53). Substitution of
the proline and glutamine residues to alanines at positions 204
and 206 in the TRAF-binding site has been demonstrated to
disrupt all TRAF1 and TRAF2 binding and most, but not all,
TRAF3 binding, respectively (35). In agreement with these
data, substitution of the proline and glutamine residues to
alanines in the TRAF-binding site (LMP1-204/6AA), which
has decreased TRAF3 binding (35), impaired LMP1-induced
focus formation. Accordingly, LMP1 with the substitution of
threonine at position 208 to alanine, which does not affect
TRAF binding, transformed rodent fibroblasts to levels similar
to those transformed by wild-type LMP1 (36).
FIG. 8. LMP1-mediated transformation of Rat-1 fibroblasts is inhibited by dnTRAF2 and dnTRAF3 but not dnTRAF6. (A) Rat-1 fibroblasts
stably expressing pBabe-puromycin-M3 (pBabe-M3), dnTRAF2, or dnTRAF3 were transduced with pBabe-puromycin (pBabe) or LMP1,
maintained for 14 days, stained with crystal violet, and observed for focus formation. (B) Quantitative analysis of focus formation assay of stable
Rat-1 cells expressing pBabe-puromycin (pBabe), dnTRAF2, or dnTRAF3 transduced with pBabe-puromycin or LMP1 at two serial dilutions.
Experiment was performed in triplicate with representative values of a single experiment shown.
VOL. 81, 2007 UNIQUE SIGNALING PROPERTIES OF CTAR1 9689
TRAF binding to LMP1 is also aided by the residues sur-
rounding the TRAF-binding site. While the aspartic acid res-
idue at position 209 is not necessary for TRAF binding, the
aspartic acid residue at position 210 is required for TRAF
binding (5, 52). The aspartic acid at position 210 is also part of
a destruction box motif that binds the E3-ubiquitin ligase com-
ponent homologue of Slimb (HOS), which contributes to reg-
ulating LMP1-mediated IB	-dependent NF-B signaling (34,
48). These data are corroborated by the finding in this study
that 1-208 is nontransforming even though an intact TRAF-
binding site is present. Interestingly, although 1-208 is non-
transforming, it is still able to modulate effects on GSK3, Rb,
p27Kip1, and plakoglobin, indicating that some signal transduc-
tion properties remain intact. Furthermore, these data indi-
cated that activation of these pathways is not sufficient for
Rat-1 fibroblast transformation. Recently, the aspartic acid at
position 211 and the serine at position 215 have been demon-
strated to be phosphorylation sites within LMP1 (6). While
these residues have not been shown to affect TRAF binding,
their close proximity to the TRAF-binding site could regulate
TRAF-LMP1 through their phosphorylation status.
CTAR1 has been demonstrated to recruit TRAF1-TRAF2
or TRAF3-TRAF5 heterodimers, with the binding of the het-
erodimers being mutually exclusive (13). Signal transduction
mediated by the LMP1-TRAF interaction is more complex
than simply recruiting the TRAFs to LMP1. In knockout
TRAF2 and TRAF5 MEFs, TRAF6 is essential for NF-B
signaling, but in mouse lymphoma cells, TRAF3 is central for
such activation (31, 53, 54). TRAF-LMP1 interactions are fur-
ther complicated by the role of adapter molecules in mediating
binding, especially in CTAR2-TRAF binding. The finding that
coexpression of either dnTRAF2 or dnTRAF3 inhibited, but
did not fully block, LMP1-mediated transformation indicates
that TRAF2 and TRAF3 are important factors in transforma-
tion but that other TRAFs (e.g., TRAF1 and TRAF5) can also
contribute to transformation.
The data in this study extend the important and unique
properties of CTAR1, which is necessary for B-lymphocyte
transformation by EBV as well as for LMP1-mediated trans-
formation of rodent fibroblasts (25, 33). CTAR1 has the
unique ability to induce expression of EGFR and TRAF1 and
can deregulate molecules involved in G1/S cell cycle progres-
sion, such as Id1, the CDK inhibitor p27Kip1, CDK2, and Rb
(13, 18, 27, 30, 35–37). Although CTAR1 is not as effective as
CTAR2 in activation of NF-B reporter constructs, CTAR1
induces specific forms of NF-B through both canonical and
noncanonical pathways and is primarily responsible for the
activation of the PI3K-Akt signaling pathway (1, 11, 32, 33, 37,
45, 50).
In this study, the activation of the PI3K-Akt-GSK3 signal-
ing pathway, the deregulation of several cellular markers in-
volved in G1/S cell cycle progression and the cell adhesion
protein plakoglobin were mapped to the TRAF-binding site
within CTAR1, which was required in the context of a trun-
cated molecule. However, deletion or mutation of CTAR1 in
full-length LMP1 revealed that another signaling motif in
LMP1 can augment LMP1-mediated activation of the PI3K-
Akt-GSK3 pathway, deregulate cell cycle markers, such as
p27Kip1, Rb, and CDK2, and decrease levels of plakoglobin.
The motif associated with this redundancy in LMP1-mediated
signaling does not appear to be CTAR2, as mutation of both
CTAR1 and CTAR2 (A5-Y384G or A5-378Stop) could still
decrease levels of p27 Kip1.
The absolute requirement for CTAR1 in a truncated form of
LMP1 but not in full-length LMP1 suggests that the motif that
provides signaling redundancy is located between amino acids
220 and 378. Importantly, this motif is not sufficient for trans-
formation, as ablation of CTAR1 in any context yields a non-
transforming phenotype. Putative Janus kinase 3-binding sites
have been identified in the region between CTAR1 and
CTAR2; however, the ability of LMP1 to bind and activate
Janus kinase 3 has been controversial (21, 22). Another motif
of interest is a putative TRAF-binding site between amino
acids 320 and 324, although deletion of amino acids 232 to 351
did not affect TRAF binding to CTAR1 (23).
In this study, ERK1/2 activation was mapped to CTAR1,
and this activation was shown to be necessary for LMP-1 me-
diated transformation of rodent fibroblasts. LMP1-mediated
transformation and ERK1/2 activation are mediated by
MEK1/2, as inhibition of MEK1/2 by the chemical inhibitor
U0126 blocked both transformation and ERK1/2 activation.
ERK1/2 responds to various mitogens and growth factors and
can initiate changes in cellular proliferation and differentia-
tion. The ability of LMP1 to affect RECK, a metastasis sup-
pressor gene, is dependent on ERK activation, and LMP1-
induced ERK1/2 activation has been demonstrated to be
mediated by TRAF2 and TRAF5 in T cells (7, 31).
The requirement for ERK1/2 activation in transformation
was supported by the inhibition of ERK1/2 activation by
dnTRAF2 and the partial inhibition by dnTRAF3, both of
which decreased transformation. These data suggest that
TRAF2 and TRAF3 are important factors in LMP1-mediated
FIG. 9. LMP1-induced activation of ERK1/2 is inhibited by
dnTRAF2 and dnTRAF3. Rat-1 cells stably expressing pBabe-puro-
mycin (pBabe), dnTRAF2, dnTRAF3, or dnTRAF6 were transduced
with pHSCG or LMP1 and assayed for expression with antibodies
against LMP1, dnTRAF2, dnTRAF3, dnTRAF6, phosphorylated
PKC (p-PKC), phosphorylated ERK1/2 (p-ERK1/2), and total
ERK1/2. Ponceau S-stained membrane was used to confirm equal
loading.
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activation of ERK1/2 in the context of rodent fibroblast trans-
formation. A major difference between the transformation of
rodent fibroblasts by LMP1 and B-lymphocyte immortalization
by EBV is that activation of NF-B is not required for rodent
fibroblast transformation but is absolutely essential for immor-
talization of B lymphocytes. Activation of PI3 kinase is re-
quired for both rodent fibroblast and B-lymphocyte transfor-
mation. It will be interesting to determine the requirement for
ERK1/2 activation in the transformation of B lymphocytes by
EBV. Different cellular environments are likely to require the
activation and inactivation of different cellular pathways. In-
deed, LMP1 signaling has been demonstrated to be regulated
in part by the ratio of TRAFs bound to its signaling domains
(53), and different cell types likely have different endogenous
levels of the different TRAFs.
We have previously shown that CTAR1-induced activation
of PI3K-Akt signaling, but not IB	-dependent NF-B-signal-
ing, is necessary for Rat-1 fibroblast transformation (33). The
data presented in this study indicate that while the activation of
PI3K-Akt signaling and deregulation of cell cycle markers as-
sociated in G1/S transition are necessary, these properties are
not sufficient for rodent fibroblast transformation. The activa-
tion of ERK1/2 signaling by only those LMP1 constructs that
have a transforming phenotype underscores the importance of
ERK1/2 activation in LMP1-mediated transformation. It is
becoming clear that LMP1 induces a variety of stimuli to affect
cellular expression and induce transformation and that at least
several of these signal transduction pathways are needed to
work in unison for transformation to take place.
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